Cellular Biomedicine Group Inc (NASDAQ:CBMG) – Analysts at Cantor Fitzgerald issued their FY2019 earnings per share estimates for Cellular Biomedicine Group in a research report issued to clients and investors on Tuesday, June 25th, according to Zacks Investment Research. Cantor Fitzgerald analyst V. Kumar forecasts that the biotechnology company will post earnings of ($2.05) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $27.00 target price on the stock. Cantor Fitzgerald also issued estimates for Cellular Biomedicine Group’s FY2020 earnings at ($2.05) EPS.
Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.06. The company had revenue of $0.05 million for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%.
Separately, BidaskClub raised Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $27.50.
Cellular Biomedicine Group stock traded down $0.16 on Thursday, reaching $13.96. The company’s stock had a trading volume of 24,100 shares, compared to its average volume of 45,038. The stock has a market capitalization of $269.22 million, a P/E ratio of -6.84 and a beta of 2.56. The company’s fifty day moving average is $15.27. Cellular Biomedicine Group has a twelve month low of $12.04 and a twelve month high of $25.00.
Several institutional investors and hedge funds have recently modified their holdings of CBMG. Nikko Asset Management Americas Inc. acquired a new position in shares of Cellular Biomedicine Group during the first quarter valued at $6,721,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Cellular Biomedicine Group during the first quarter valued at $6,622,000. ARK Investment Management LLC acquired a new position in shares of Cellular Biomedicine Group during the first quarter valued at $4,944,000. BlackRock Inc. lifted its stake in shares of Cellular Biomedicine Group by 3.8% during the fourth quarter. BlackRock Inc. now owns 657,998 shares of the biotechnology company’s stock valued at $11,620,000 after acquiring an additional 23,992 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Cellular Biomedicine Group by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 126,067 shares of the biotechnology company’s stock valued at $2,226,000 after acquiring an additional 14,621 shares during the period. 18.99% of the stock is currently owned by institutional investors and hedge funds.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.